N-(2,5-Dimethoxyphenyl)-4-methylbenzenesulfonamide, 95%, 250mg

Ethyl 2-chlorobenzoate, 95.0%, 5g

1-(3-chlorophenyl)-3-(ethoxycarbonyl)-4,5-dihydro-1H-pyrazole-5-carboxylic acid, 95.0%, 5g

1,4-Dichloro-2,5-dibromobenzene, 95%, 25g

2-Aminobenzophenone>98.0%(GC)(T)25g

tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate, 95.0%, 10g

5-Bromo-2-(chloromethyl)pyridine, 95.0%, 5g

2,4-Dichloro-5-methyl-pyrimidine, 98.0%, 1g

5-Bromo-2,3-difluoropyridine, 95.0%, 500g

3-noradamantanecarboxylic acid, min. 99%, for synthesis, 1 g, glass packaging

1-(3-Aminopropyl)-1H-pyrrole-2,5-dione 2,2,2-trifluoroacetate, 95.0%, 1g

6'-Methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine (Etoricoxib Impurity), 97%, 50mg

3-(S-Methylsulfonimidoyl)benzoic acid, 100mg